Download PDF
Pneumologie 2002; 56(2): 113-131
DOI: 10.1055/s-2002-20093
Empfehlungen
Georg Thieme Verlag Stuttgart · New York

Empfehlungen zur Therapie des Bronchialkarzinoms

Gemeinsame Empfehlung der Deutschen Gesellschaft für Pneumologie (DGP), der Deutschen Gesellschaft für Radioonkologie (DEGRO), der Deutschen Gesellschaft für Thoraxchirurgie (DGT) und der Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft (AIO)Recommendations on the Therapy of Bronchial CarcinomaM.  Thomas,1 , M.  Baumann,1 , M.  Deppermann,1 , L.  Freitag,1 , U.  Gatzemeier,1 , R.  Huber,1 , B.  Passlick,1 , M.  Serke,1 , D.  Ukena,1
  • 1Klinik für Hämatologie, Onkologie und Pneumologie, Medizinische Klinik A, Universitätsklinikum Münster
Further Information

Publication History

Publication Date:
13 February 2002 (online)

Also available at
   Permissions and Reprints

Literatur

  • 1 Mountain C. Revisions in the international system for staging lung cancer.  Chest. 1997;  111 1710-1717
    CrossrefPubMedGoogle Scholar
  • 2 Thomas M, Gatzemeier U, Goerg R, Matthiessen W, Morr H, Schönfeld N, Ukena D, Stamatis G. Empfehlungen zur Diagnostik des Bronchialkarzinoms.  Pneumologie. 2000;  54 361-371
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Pignon J P, Arriagada R, Ihde D C, Johnson D H, Perry M C, Souhami R L, Brodin O, Joss R A, Kies M S, Lebeau B. et al . A metaanalysis of thoracic radiotherapy for small cell lung cancer.  N Engl J Med. 1992;  327 1618-1624
    CrossrefPubMedGoogle Scholar
  • 4 Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis.  J Clin Oncol. 1992;  10 890-895
    CrossrefPubMedGoogle Scholar
  • 5 Murray N, Coy P, Pater J L, Hodson I, Arnold A, Zee B C, Payne D, Kostashuk E, Evans W, Dixon P, Sadura A, Feld R, Levitt M, Wierzbicki R, Ayoub J, Maroun J, Wilson K. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer.  J Clin Oncol. 1993;  11 336-344
    PubMedGoogle Scholar
  • 6 Jeremic B, Shibamoto Y, Acimovic L, Milisavlejevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer. A randomized study.  J Clin Oncol. 1997;  15 893-899
    PubMedGoogle Scholar
  • 7 Goto K, Nishiwaki Y, Takada M, Fukuoka M, Kawahara M, Sugiara T, Kurita Y, Watanabe K, Noda K, Yoshimura K, Tamura T, Saijo N. Final results of a phase-III-study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (P) and etoposide (E) for limited-stage small cell lung cancer (LD-SCLC). The Japan Clinical Oncology Group (JCOG) Study.  Proc Am Soc Clin Oncol. 1999;  18 468a (abs. 1805)
    PubMedGoogle Scholar
  • 8 Work E, Nielsen O, Bentzen S, Fode K, Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer.  J Clin Oncol. 1997;  15 3030-3037
    PubMedGoogle Scholar
  • 9 Perry M, Eaton W, Propert K, Ware J, Zimmer B, Chahinian P, Skarin A, Carey R, Kreisman H, Faulkner C, Comis R, Green M. Chemotherapy with or without radiation therapy in limited small-cell lung cancer.  N Engl J Med. 1987;  316 912-918
    CrossrefPubMedGoogle Scholar
  • 10 Perry M, Herndon J, Eaton W, Green M. Thoracic radiation therapy added to chemotherapy in limited small cell lung cancer: an update of cancer and leukemia group B (CALGB) study 8083.  Proc Am Soc Clin Oncol. 1996;  15 384 (abs. 1150)
    PubMedGoogle Scholar
  • 11 Turrisi A, Kim K, Blum R, Sause W T, Livingston R B, Komaki K, Wagner H, Aisner S, Johnson D. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.  N Engl J Med. 1999;  340 265-271
    CrossrefPubMedGoogle Scholar
  • 12 Auperin A, Arriagada R, Pignon J P, Le Pechooux C, Gregor A, Stephens R J, Kristjansen P EG. Prophylactic cranial irridiation for patients with small-cell lung cancer in complete remission.  N Engl J Med. 1999;  341 476-484
    CrossrefPubMedGoogle Scholar
  • 13 Shepherd F A, Ginsberg R J, Patterson G A, Evans W K, Feld R. A prospective study of adjuvant surgical resection after chemotherapy for limited small-cell lung cancer. A University of Toronto Lung Oncology Group Study.  J Thorac Cardiovasc Surg. 1989;  97 177-186
    PubMedGoogle Scholar
  • 14 Davis S, Crino L, Tonato M, Darwish S, Pelicci P G. A prospective analysis of chemotherapy following surgical resection of clinical stage I - II small-cell lung cancer.  Am J Clin Oncol. 1993;  16 93-95
    PubMedGoogle Scholar
  • 15 Karrer K, Shields T W, Denck H, Hrabar B, Vogt-Moykopf I, Salzer G M. The importance of surgical and multimodality treatment for small-cell bronchial carcinoma.  J Thorac Cardiovasc Surg. 1989;  97 168-176
    PubMedGoogle Scholar
  • 16 Kaiser D, Fritzsche A, Matthiessen W. Operationsindikation beim kleinzelligen Bronchialkarzinom.  Dtsch Med Wochenschr. 1992;  117 103-106
    PubMedGoogle Scholar
  • 17 Jeremic B, Shibamoto Y, Nicolic N, Milicic B, Milisavljevic S, Dagovic A, Aleksandrovic J, Radosavljevid-Asic G. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study.  Journal of Clinical Oncology. 1999;  17 2092-2099
    PubMedGoogle Scholar
  • 18 Pearson F G, De Larue N C, Ilves R, Todd T R, Cooper J D. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung.  J Thorac Cardiovasc Surg. 1982;  83 1-11
    PubMedGoogle Scholar
  • 19 Pitz C C, Brutel-de I R, Elbers H R, Westermann C J, van den Bosch J. Surgical treatment of 125 patients with non-small cell lung cancer and chest wall involvement.  Thorax. 1996;  51 846-850
    PubMedGoogle Scholar
  • 20 Gould P M, Bonner J A, Sawyer T E, Deschamps C, Lange C M, Li H. Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non-small cell lung cancer.  Int J Radiat Oncol Biol Phys. 1999;  45 91-95
    CrossrefPubMedGoogle Scholar
  • 21 Paulson D L. The role of preoperative radiation therapy in the surgical management of cacinoma in the superior pulmonary sulcus.  Front Radiat Ther Oncol. 1970;  5 177-187
    PubMedGoogle Scholar
  • 22 Ahmad K, Fayos J V, Kirsh M M. Apical lung carcinoma.  Cancer. 1984;  54 913-917
    PubMedGoogle Scholar
  • 23 Attar S, Krasna M J, Sonett J R, Hankins J R, Slawson R G, Suter C M, McLaughlin J S. Superior sulcus (Pancoast) tumor: experience with 105 patients [see comments].  Ann Thorac Surg. 1998;  66 193-198
    CrossrefPubMedGoogle Scholar
  • 24 Paulson D L. Carcinomas in the superior pulmonary sulcus.  J Thorac Cardiovasc Surg. 1975;  70 1095-1104
    PubMedGoogle Scholar
  • 25 Maggi G, Casadio C, Pischedda F, Giobbe R, Cianci R, Ruffini E, Molinatti M, Mancuso M. Combined radiosurgical treatment of Pancoast tumor.  Ann Thorac Surg. 1994;  57 198-202
    CrossrefPubMedGoogle Scholar
  • 26 Stuschke M, Heilmann H P. Lunge und Mediastinum. In: Scherer E, Sack H (Hrsg). Strahlentherapie, 4. Aufl. Berlin: Springer 1996: 683-718
    Google Scholar
  • 27 Arcasoy S M, Jett J R. Superior pulmonary sulcus tumors and pancoast syndrome.  N Engl J Med. 1997;  337 1370-1376
    CrossrefPubMedGoogle Scholar
  • 28 Ichinose Y, Hara N, Ohta M, Yano T, Maeda K, Asoh H, Katsuda Y. Is T factor of the TNM staging system a predominat prognostic factor in pathologic stage I non-small cell lung cancer?.  J Thorac Cardiovasc Surg. 1993;  106 90-94
    PubMedGoogle Scholar
  • 29 Mountain C. New prognostic factors in lung cancer.  Chest. 1995;  108 246-254
    CrossrefPubMedGoogle Scholar
  • 30 Cote R J, Beattie E J, Chaiwun B, Shi S R, Harvey J, Chen S C, Sherrod A E, Groshen S, Taylor C R. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma.  Ann Surg. 1995;  222 415-425
    PubMedGoogle Scholar
  • 31 Passlick B, Kubuschok B, Izbicki J R, Thetter O, Pantel K. Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer.  Ann Thorac Surg. 1999;  68 2053-2058
    CrossrefPubMedGoogle Scholar
  • 32 Thomas M, Macha H N, Rübe C, van de Loo J. Stellenwert der Chemotherapie in der Behandlung des nicht-kleinzelligen Bronchialkarzinoms.  Dtsch med Wschr. 1995;  120 1627-1630
    PubMedGoogle Scholar
  • 33 PORT. Meta-analysis Trialists Group . Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from 9 randomized controlled trials.  Lancet. 1998;  352 257-263
    CrossrefPubMedGoogle Scholar
  • 34 Klages H T, Stuschke M. Postoperative Radiotherapie beim kurativ resezierten nicht-kleinzelligen Bronchialkarzinom.  Strahlenther Onkol. 1999;  175 134-138
    PubMedGoogle Scholar
  • 35 Rosell R, Gomez-Codina J, Camps C, Ryan M B, Putnam J B, Lee L S, Dhingra H, De Caro L, Chasen M, McGavran M, Atkinson E N, KiHong W. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.  N Engl J Med. 1994;  330 153-158
    CrossrefPubMedGoogle Scholar
  • 36 Roth J, Fossela F, Komaki R, Ryan M B, Putnam J B, Lee L S, Dhingra H, De Caro L, Chasen M, McGavran M, Atkinson E N, KiHong W. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.  J Natl Cancer Inst. 1994;  86 673-680
    CrossrefPubMedGoogle Scholar
  • 37 Albain K S, Rusch V W, Crowley J J, Rice T W, Turrisi A T, Weick J K, Lonchyna V A, Presant C A, McKenna R J, Gandara D R, Fosmire H, Taylor S A, Stelzer K J, Beasley K R, Livingston R B. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.  J Clin Oncol. 1995;  13 1880-1892
    CrossrefPubMedGoogle Scholar
  • 38 Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Müller M R, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.  J Clin Oncol. 1998;  16 622-634
    PubMedGoogle Scholar
  • 39 Thomas M, Rübe C, Semik M, von Eiff M, Freitag L, Macha H N, Wagner W, Klinke F, Sheld H H, Willich N, Berdel W E, Junker H. Chemotherapy and subsequent twice-daily chemoradiation before surgery in stage III non-small cell lung cancer: impact of tumor regression on survival.  J Clin Oncol. 1999 (a);  17 1185-1193
    PubMedGoogle Scholar
  • 40 Thomas M, Rübe C, Semik M, Steppling H, Macha H, Deimling A, Klinke F, Deppermann K, Clemens M, Dornoff W, Weber W, Berdel W. Randomized trial of chemotherapy and twice-daily chemoradiation versus chemotherapy alone before surgery in stage III non-small cell lung cancer: interim of toxicity.  Proc am Soc Clin Oncol. 1999 (b);  18 458a (abs. 1769)
    PubMedGoogle Scholar
  • 41 Dillman R O, Seagren S L, Propert K J, Guerra J, Eaton W L, Perry M C, Carey R W, Frei E F, Green M R. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.  N Engl J Med. 1990;  323 940-945
    CrossrefPubMedGoogle Scholar
  • 42 Le Chevalier T, Arriagda R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe Terrier M J, Douillard J Y, Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients.  J Natl Cancer Inst. 1991;  83 417-423
    CrossrefPubMedGoogle Scholar
  • 43 Le Chevalier T, Arriagda R, Tarayre M, Lacombe Terrier M J, Laplanche A, Quoix E, Ruffie P, Martin M, Douillard J Y. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma (letter).  J Natl Cancer Inst. 1992;  84 58
    PubMedGoogle Scholar
  • 44 Sause W T, Scott C, Taylor S, Johnson D, Livingstone R, Komaki R, Emami B, Curran W J, Byhardt R W, Turrisi A T, Dar A R, Cox J D. Radiation Therapy Oncology Group (RTOG) 80-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer.  J Natl Cancer Inst. 1995;  87 198-205
    PubMedGoogle Scholar
  • 45 Sause W, Kolesar P, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran W, Byhardt R, Dar A, Turrisi A. Final results of phase III trial in regionally advanced non-small cell lung cancer. RTOG, ECOG and SWOG.  Chest. 2000;  117 358-364
    CrossrefPubMedGoogle Scholar
  • 46 Dillman R O, Herndon J, Seagren S L, Eaton W L, Green M R. Improved survival in stage III non-small cell lung cancer: seven year follow up of CALGB 8433 trial.  J Natl Cancer Inst. 1996;  88 1210-1215
    CrossrefPubMedGoogle Scholar
  • 47 American Society of Clinical Oncology . Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer.  J Clin Oncol. 1997;  15 2996-3018
    PubMedGoogle Scholar
  • 48 Choi N, Baumann M, Flentje M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N, Kosmidis P. Predictive factors of radiation response in non-small cell lung cancer: present status.  Lung Cancer. 2001;  31 43-56
    CrossrefPubMedGoogle Scholar
  • 49 Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicenter trial.  Lancet. 1997;  350 161-165
    CrossrefPubMedGoogle Scholar
  • 50 Schaake-Konig C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout H, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A, Renaud A, Rodrigus P, Schuster-Uitterhoeve L, Sculier J P, van Zandwijk N, Bartelink H. Effects of concomittand cisplatin and radiotherapy on inoperable non-small-cell lung cancer.  N Engl J Med. 1992;  326 524-530
    PubMedGoogle Scholar
  • 51 Jeremic B, Shibamoto L, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer.  J Clin Oncol. 1995;  13 452-458
    PubMedGoogle Scholar
  • 52 Jeremic B, Shibamoto L, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.  J Clin Oncol. 1996;  14 1065-1070
    CrossrefPubMedGoogle Scholar
  • 53 Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with Mitomycin, Vindesine, and Cisplatin in unresectable stage III non-small lung cancer.  J Clin Oncol. 1999;  17 2692-2699
    CrossrefPubMedGoogle Scholar
  • 54 Curran W, Scott C, Langer C, Komaki R, Lee J, Hauser S, Movsas B, Wassermann T, Rosenthal S, Byhardt R, Sause W, Cox J. Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer: Initial report of Radiation Therapy Oncology Group (RTOG) 9410.  Proc Am Soc Clin Oncol. 2000;  19 484a (abs. 1891)
    PubMedGoogle Scholar
  • 55 Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Parmar M. (on behalf of the CHART steering committee) . Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: mature data from the randomised multicentre trial.  Radiother Oncol. 1999;  52 137-148
    CrossrefPubMedGoogle Scholar
  • 56 Baumann M. Accelerated radiation therapy in non-small cell lung cancer.  Radiother Oncol. 1999;  52 97-99
    CrossrefPubMedGoogle Scholar
  • 57 Baumann M, Appold S, Zips D, Nestele U, Petersen C, Herrmann Th. Modified fractionation in the radical treatment of non-small cell lung cancer.  Front Radiat Ther Oncol. 2000;  34 80-88
    PubMedGoogle Scholar
  • 58 Baumann M, Herrmann T, Matthiessen W, Koch R, Strelocke K, Paul U. für das CHARTWEL-Bronchus Protokollkomitee (1997) CHARTWEL-Bronchus (ARO 97-1) . Eine randomisiert-multizentrische Studie zum Vergleich einer konventionell fraktionierten Strahlentherapie mit CHARTWEL-Bestrahlung bei inoperablen nicht-kleinzelligen Bronchialkarzinomen.  Strahlenther Onkol. 1997;  173 663-667
    PubMedGoogle Scholar
  • 59 Thomas M. Tumorassoziierte Prognoseparameter beim nicht-kleinzelligen Bronchialkarzinom.  Pneumologie. 1997;  51 669-677
    PubMedGoogle Scholar
  • 60 Thomas M, Rübe C, Semik M, von Eiff M, Klinke F, Macha H N, Freitag L, Scheld H H, Willich N, Berdel W E, Junker K. Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence by pretherapeutic assessment of p185neu.  Eur Respir J. 1999(c);  13 424-429
    CrossrefPubMedGoogle Scholar
  • 61 Non-small cell lung cancer collaborative group . Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials.  BMJ. 1995;  311 899-909
    Google Scholar
  • 62 Le Chevalier T. Chemotherapy for advanced non-small cell lung cancer.  Chest. 1996;  109 107s-109s
    PubMedGoogle Scholar
  • 63 Ellis P A, Smith I, Hardy J, Nicolson M, Talbot D, Ashley S, Priest K. Symptom relief with MVP (mitomycin C, vinblastin and cisplatin) chemotherapy in advanced non-small cell lung cancer.  Br J Cancer. 1995;  71 366-370
    PubMedGoogle Scholar
  • 64 Thatcher N, Niven R M, Anderson H. Agressive versus nonaggressive therapy for metastatic non-small cell lung cancer.  Chest. 1996;  109 87s-92s
    PubMedGoogle Scholar
  • 65 Wirbel R J, Mutschler W E. Die chirurgische Therapie von Knochenmetastasen.  Zentralbl Chir. 1995;  120 707-715
    PubMedGoogle Scholar
  • 66 Janjan N A. Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals.  Cancer. 1997;  80 1628-1645
    CrossrefPubMedGoogle Scholar
  • 67 Sullivan F J. Palliative radiotherapy for lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT (ed). Lung Cancer. Principles and Practice. Philadelphia-New York: Lippincott-Raven 1996: 775-789
    Google Scholar
  • 68 Berenson J R, Lichtenstein A, Porter L, Dimopoulos M A, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone J, Reitsma D, Heffernan M, Seaman J, Knight R. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma.  N Engl J Med. 1996;  334 488-493
    CrossrefPubMedGoogle Scholar
  • 69 Hortobagyi G N, Theriault R L, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone J F, Seaman J, Knight R D. Efficacy of pamidronate in reducing skeletal compliancations in patients with breast cancer and lytic bone metastases.  N Engl J Med. 1996;  335 1785-1791
    CrossrefPubMedGoogle Scholar
  • 70 Theriault R L, Lipton A, Hortoagyi G N, Leff R, Glück S, Stewart J F, Costello S, Kennedy I, Simeone J, Seaman J J, Knight R D, Mellars K, Heffernan M, Reitsma D J. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial.  J Clin Oncol. 1999;  17 846-854
    PubMedGoogle Scholar
  • 71 Ryan G F, Ball D L, Smith J G. Treatment of brain metastases from primary lung cancer.  Int J Radiat Oncol Biol Phys. 1995;  31 273-278
    CrossrefPubMedGoogle Scholar
  • 72 Patchell R A, Tibbs P A, Walsh J W, Dempsey R J, Maruyama Y, Kryscio R J, Markesbery W R, Macdonald J S, Young B. A randomized trial of surgery in the treatment of single metastases to the brain.  N Engl J Med. 1990;  322 494-500
    CrossrefPubMedGoogle Scholar
  • 73 Sause W T, Crowley J J, Morantz R, Rotman M, Mowry P A, Bouzaglou A, Borst J R, Selin H. Solitary brain metastasis: results of an RTOG/SWOG protocol evaluation surgery + RT versus RT alone.  Am J Clin Oncol. 1990;  13 427-432
    PubMedGoogle Scholar
  • 74 Cho K H, Hall W A, Gerbi B J, Higgins P D, Bohen M, Clark H B. Patient selection criteria for the treatment of brain metastases with sterotactic radiosurgery.  J Neurooncol. 1998;  40 73-86
    CrossrefPubMedGoogle Scholar
  • 75 Flickinger J C, Lunsford L D, Somaza S, Konziolka D. Radiosurgery: its role in brain metastasis management.  Neurosurg Clin N Am. 1996;  7 497-504
    PubMedGoogle Scholar
  • 76 Dempke W, Behrmann C, Schöber C, Büchele T, Grothey A, Schmoll H-J. Diagnostisches und therapeuptisches Management der oberen Einflussstauung.  Med Klinik. 1999;  94 681-684
    PubMedGoogle Scholar
  • 77 Markman M. Diagnosis and management of superior vena cava syndrome.  Cleve Clin J Med. 1999;  66 59-61
    CrossrefPubMedGoogle Scholar
  • 78 Ostler P J, Clarke D P, Watkinson A F, Gaze M N. Superior vena cava obstruction: a modern management strategy.  Clin Oncol R Coll Radiol. 1997;  9 83-89
    CrossrefPubMedGoogle Scholar
  • 79 Hochrein J, Bashore T M, O'Laughin M P, Harrison K. Percutaneous stenting of superior vena cava syndrome: a case report and review of theliterature.  Am J Med. 1998;  104 78-84
    CrossrefPubMedGoogle Scholar
  • 80 Nesbitt J C. Surgical management of superior vena cava syndrome. In: Pass HJ, Mitchell JB, Johnson DH, Turrisi AT (eds). Lung Cancer. Principles and Practice Philadelphia-New York: Lippincott-Raven 1996: 671-681
    Google Scholar
  • 81 Byrne T N. Spinal cord compression from epidural metastases.  N Engl J Med. 1992;  327 614-619
    CrossrefPubMedGoogle Scholar
  • 82 Soerensen S, Helweg-Larsen S, Mouridsen H, Hansen H H. Effect of high-dose dexamethasone in carcinomateous metastatic spinal cord compression treated with radiotherapy: a randomised trial.  Eur J Cancer. 1994;  30A 22-27
    PubMedGoogle Scholar
  • 83 Bach F, Agerlin N, Sorensen J B, Rasmussen T B, Dombernowsky P, Sorensen P S, Hansen H H. Metastatic spinal cord compression secondary to lung cancer.  J Clin Oncol. 1992;  10 1781-1787
    PubMedGoogle Scholar
  • 84 Loblaw D A, Laperriere N J. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline.  J Clin Oncol. 1998;  16 1613-1624
    PubMedGoogle Scholar
  • 85 Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial.  Int J Radiat Oncol Biol Phys. 1995;  32 959-967
    CrossrefPubMedGoogle Scholar
  • 86 Solberg A, Bremnes R M. Metastatic spinal cord compression: diagnostic delay, treatment, and outcome.  Anticancer Res. 1999;  19 677-684
    PubMedGoogle Scholar
  • 87 Loddenkemper R. Thoracoscopy - state of the art.  Eur Respir J. 1998;  11 213-221
    CrossrefPubMedGoogle Scholar
  • 88 Rodriguez-Panadero F, Antony V B. Pleurodesis: state of the art.  Eur Respir J. 1997;  10 1648-1654
    CrossrefPubMedGoogle Scholar
  • 89 Hentrich M, Hartenstein R. Behandlung maligner Körperhöhlenergüsse.  Internist. 1997;  38 794-804
    PubMedGoogle Scholar
  • 90 Waller D A, Morritt G N, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion.  Chest. 1995;  107 1454-1456
    PubMedGoogle Scholar
  • 91 Berg M, Heisel A, Ukena D, Schäfers H-J, Schieffer H. Behandlung des malignen Perikardergusses.  Med Klinik. 1997;  92 27-30
    PubMedGoogle Scholar
  • 92 Cherny N I, Portenoy R K. The management of cancer pain.  CA Cancer J Clin. 1994;  44 263-303
    PubMedGoogle Scholar
  • 93 World Health Organization [WHO] . Cancer pain relief. With a guide to opioid availability.  Cancer Pain Relief. 1996;  1-63
    PubMedGoogle Scholar
  • 94 Zech D F, Grond S, Lynch J, Hertel D, Lehmann K A. Validation of World Health Organization guidelines for cancer pain relief. A 10-year prospective study.  Pain. 1995;  63 65-76
    CrossrefPubMedGoogle Scholar
  • 95 Bone Pain Trial Working Party . 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomized comparison with a multifraction schedule over 12 months of patient follow-up.  Radiother Oncol. 1999;  52 111-121
    CrossrefPubMedGoogle Scholar
  • 96 Reichle G, Freitag L, Kullmann H J, Prenzel R, Macha H N, Farin G. Argon plasma coagulation in bronchology: a new method - alternative or complementary.  J Bronchol. 2000;  7 109-117
    PubMedGoogle Scholar
  • 97 Medical Research Concil Lung Cancer Working Party . A Medical Research Council (MRC) randomized trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status.  Br J Cancer. 1992;  65 934-941
    PubMedGoogle Scholar
  • 98 Medical Research Concil Lung Cancer Working Party . Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small-cell lung cancer and good performance status.  Clinical Oncol. 1996;  8 167-175
    PubMedGoogle Scholar
  • 99 Speiser B L, Spratling L. Remote afterloading brachytherapy for the local control of endobronchial carcinoma.  Int J Radiation Oncology Biol Phys. 1993;  25 579-587
    PubMedGoogle Scholar
  • 100 Freitag L, Tekolf E, Stamatis G, Montag M, Greschuchna D. Three years experience with a new balloon catheter for the management of hemoptysis.  Europ Res J. 1994;  7 2033-2037
    PubMedGoogle Scholar
  • 101 Stoll J F, Bettmann M A. Bronchial artery embolization to control hemoptysis: a review.  Cardiovasc Intervent Radiol. 1988;  11 263-269
    CrossrefPubMedGoogle Scholar
  • 102 Zhang J S, Cui Z P, Wang M Q, Yang L. Bronchial arteriography and transcatheter embolization in the management of hemoptysis.  Cardiovasc Intervent Radiol. 1994;  17 276-279
    PubMedGoogle Scholar
  • 103 Deutsche Gesellschaft für Pneumologie . Empfehlungen zur bronchoskopischen Behandlung tracheobronchialer Verschlüsse, Stenosen und muraler maligner Tumoren.  Pneumologie. 1998;  52 243-248
    PubMedGoogle Scholar
  • 104 Mathissen D J, Grillo H C. Endoscopic relief of malignant airway obstruction.  Ann Thorac Surg. 1998;  48 469-475
    PubMedGoogle Scholar
  • 105 Cavaliere S, Foccoli P, Tonielli C, Feijo S. Nd-YAF laser therapy in lung cancer. An 11 year experience with 2253 applications in 1585 patients.  J Bronchol. 1994;  1 105-111
    PubMedGoogle Scholar
  • 106 Macha H N, Becker K O, Kemmer H P. Pattern of failure and survival in endobronchial laser resection: a matched pair study.  Chest. 1994;  105 1668-1672
    CrossrefPubMedGoogle Scholar
  • 107 Vergnon J M, Mathur P N. Cryotherapy for endobronchial disorders. In: Boliger CT, Mathur PN (Hrsg). Interventional Bronchoscopy Prog Respir Res Basel: Karger 2000 Vol 30: 133-145
    Google Scholar
  • 108 Sutedja G, van Boxem T J, Schramel F M, Felius v C, Postmus P E. Endobronchial electrocautery is an excellent alternative for Nd: YAG laser to treat airway tumors.  J Bronchol. 1997;  4 101-105
    CrossrefPubMedGoogle Scholar
  • 109 Sutedja G, Bolliger C. Endothelial electrocautery and argon plasma coagulation. In: Bolliger CT, Mathur PN (Hrsg). Interventional Bronchoscopy Prog Respir Res Basel: Karger 2000 30: 120-132
    Google Scholar
  • 110 Maiwand M O, Homasson J P. Cryotherapy for tracheobronchial disorders. In: Mathur PN, Beamis JF (Hrsg). Clinics in Chest Medicine Philadelphia: Saunders 1995 Vol 16: 427-443
    Google Scholar
  • 111 Sutedja T G, Postmus P E. Photodynamic therapy in lung cancer. A review.  J Photochem Photobiol B. 1996;  36 199-204
    CrossrefPubMedGoogle Scholar
  • 112 Freitag L, Korupp A, Itzigehl I, Dankwart F, Tekolf E, Reichle G, Kullmann H J, Macha H N. Erfahrungen mit Fluoreszenzdiagnostik und photodynamischer Therapie im multimodalen Behandlungskonzept des operierten rezidivierenden Bronchialkarzinoms.  Pneumologie. 1996;  50 693-699
    PubMedGoogle Scholar
  • 113 George P JM, Garrett C PO, Nixon C, Hetzel M R, Nanson E M, Millard F J. Laser treatment for tracheobronchial tumors: local or general anesthesia?.  Thorax. 1987;  42 656-660
    CrossrefPubMedGoogle Scholar
  • 114 Macha H N, Wahlers B, Reichle G, von Zwehl D. Endobronchial radiation therapy for obstructing malignancies: ten years' experience with iridium-192 high-dose radiation brachytherapy afterloading technique in 365 patients.  Lung. 1995;  173 271-280
    PubMedGoogle Scholar
  • 115 Huber R M, Fischer R, Hautmann H, Pollinger B, Wendt T, Müller-Wening D, Häussinger K. Palliative endobronchial bradytherapy for central lung tumors. A prospective, randomized comparison of two fractionation schedules.  Chest. 1995;  107 463-470
    PubMedGoogle Scholar
  • 116 Huber R M, Fischer R, Hautmann H, Pollinger B, Häussinger K, Wendt T. Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central tumors.  Int J Radiat Oncol Biol Phys. 1997;  38 533-540
    CrossrefPubMedGoogle Scholar
  • 117 Freitag L. Tracheobronchial stents. In: Bolliger CT, Mathur PN (Hrsg). Interventional Bronchoscopy Pro Respir Res Basel: Karger 2000 30: 171-186
    Google Scholar
  • 118 Sutedja G, Schramel F, van Kralingen K, Postmus P E. Stent placement is justifiable in endstage patients with malignant airway tumors.  Respiration. 1995;  62 148-150
    PubMedGoogle Scholar
  • 119 Silvestri G A, Handy J, Lackland D, Corley E, Reed C E. Specialists achieve better outcomes than generalists for lung cancer surgery [see comments].  Chest. 1998;  114 675-680
    CrossrefPubMedGoogle Scholar
  • 120 Duque J L, Ramos G, Castrodeza J, Cerezal J, Castanedo M, Yuste M G, Heras F. Early complications in surgical treatment of lung cancer: a prospective, multicenter study. Grupo Cooperativo de Carcinoma Broncogenico de la Sociedad Espanola de Neumologia y Cirugia Toracica.  Ann Thorac Surg. 1997;  63 944-950
    CrossrefPubMedGoogle Scholar
  • 121 Ginsberg R J, Hill L D, Eagan R T, Thomas P, Mountain C F, Deslauriers J, Fry W A, Butz R O, Goldberg M, Waters P F. Modern thirty-day operative mortality for surgical resections in lung cancer.  J Thorac Cardiovasc Surg. 1983;  86 654-658
    CrossrefPubMedGoogle Scholar
  • 122 Warren W H, Faber L P. Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma.  J Thorac Cardiovasc Surg. 1994;  107 1087-1094
    PubMedGoogle Scholar
  • 123 Wahi R, McMurtrey M J, DeCaro L F, Mountain C F, Ali M K, Smith T L, Roth J A. Determinants of perioperative morbidity and mortality after pneumonectomy.  Ann Thorac Surg. 1989;  48 33-37
    CrossrefPubMedGoogle Scholar
  • 124 Klemperer J, Ginsberg R J. Morbidity and mortality after pneumonectomy.  Chest Surg Clin N Am. 1999;  9 515-525
    PubMedGoogle Scholar
  • 125 Gaissert H A, Mathisen D J, Moncure A C, Hilgenberg A D, Grillo H C, Wain J C. Survival and function after sleeve lobectomy for lung cancer.  J Thorac Cardiovasc Surg. 1996;  111 948-953
    CrossrefPubMedGoogle Scholar
  • 126 Bach P, Cramer L, Schrag D, Downey R, Gelfand S, Begg C. The influence of hospital volume on survival after resection of lung cancer.  N Engl J Med. 2001;  345 181-188
    CrossrefPubMedGoogle Scholar
  • 127 Sugi K, Kaneda Y, Esato K. Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage IA lung cancer.  World J Surg. 2000;  24 27-30
    CrossrefPubMedGoogle Scholar
  • 128 Naruke T, Tsuchiya R, Kondo H, Nakayama H, Asamura H. Lymph node sampling in lung cancer: how should it be done?.  Eur J Cardiothorac Surg. 1999;  16 Suppl 1 S17-S24
    CrossrefPubMedGoogle Scholar
  • 129 McKenna-RJ J, Wolf R K, Brenner M, Fischel R J, Wurnig P. Is lobectomy by video-assisted thoracic surgery an adequate cancer operation?.  Ann Thorac Surg. 1998;  66 1903-1908
    CrossrefPubMedGoogle Scholar
  • 130 Mack M J, Scruggs G R, Kelly K M, Shennib H, Landreneau R J. Video-assisted thoracic surgery: has technology found its place?.  Ann Thorac Surg. 1997;  64 211-215
    CrossrefPubMedGoogle Scholar
  • 131 Bernard A. Resection of pulmonary nodules using video-assisted thoracic surgery. The Thorax Group.  Ann Thorac Surg. 1996;  61 202-204
    CrossrefPubMedGoogle Scholar
  • 132 Mountain C, Dresler C. Regional lymphnode classification for lung cancer staging.  Chest. 1997;  111 1718-1723
    CrossrefPubMedGoogle Scholar
  • 133 Passlick B, Thetter O. Lymph node documentation and lymphadenectomy in bronchial carcinomas. Results of a survey in Germany.  Chirurg. 1997;  68 601-605
    CrossrefPubMedGoogle Scholar
  • 134 Schildberg F W, Dienemann H, Hoffmann H. Lymphadenektomie bei Bronchialkarzinomen: Fakten und Fiktion.  Zentralbl. 1996;  121 96-101
    PubMedGoogle Scholar
  • 135 Izbicki J R, Thetter O, Habekost M, Karg O, Passlick B, Kubuschok B, Busch C, Haeussinger K, Knoefel W T, Pantel K. Radical systematic lymphadenectomy in non-small cell lung cancer - A prospective controlled randomized clinical trial.  Brit J Surg. 1994;  81 229-235
    CrossrefPubMedGoogle Scholar
  • 136 Izbicki J R, Passlick B, Pantel K, Pichlmeier U, Hosch S B, Karg O, Thetter O. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer - Results of a prospective randomized study.  Ann Surg. 1998;  227 138-144
    CrossrefPubMedGoogle Scholar
  • 137 Luketich J D, Burt M E. Does resection of adrenal metastases from non-small-cell lung cancer improve survical?.  Ann Thorac Surg. 1996;  62 1614-1616
    CrossrefPubMedGoogle Scholar
  • 138 Mussi A, Pistolesi M, Lucchi M. et al . Resection of single brain metastasis in non-small-cell lung cancer: prognostic factors.  J Thorac Cardiovasc Surg. 1996;  112 146-153
    CrossrefPubMedGoogle Scholar
  • 139 Porte H L, Roumilhac D, Graziana J P. et al . Adrenalectomy for a solitary adrenal metastasis form lung cancer.  Ann Thorac Surg. 1998;  65 331-335
    CrossrefPubMedGoogle Scholar
  • 140 Naruke T, Tsuchiya R, Kondo H, Asamura H, Nakayama H. Implications of staging in lung cancer.  Chest. 1997;  112 242S-248S
    CrossrefPubMedGoogle Scholar
  • 141 Mountain C F. The biological operability of stage III non-small cell lung cancer.  Ann Thorac Surg. 1985;  40 60-64
    PubMedGoogle Scholar
  • 142 Inoue K, Sato M, Fujimara S, Sakurada A, Takahashi S, Usuda K, Kondo T, Tanita T, Handa M, Saito Y. Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993.  J Thorac Cardiovasc Surg. 1998;  116 407-411
    CrossrefPubMedGoogle Scholar
  • 143 Sagawa M, Sakurada A, Fujimara S, Sato M, Takahashi S, Usuda K, Endo C, Aikawa H, Kondo T, Saito Y. Five-year survivors with resected pN2 nonsmall cell lung carcinoma.  Cancer. 1999;  85 864-868
    CrossrefPubMedGoogle Scholar
  • 144 Kreisman H, Wolkove N, Quoix E. Small cell lung cancer presenting as a solitary pulmonary nodule.  Chest. 1992;  101 225-231
    PubMedGoogle Scholar
  • 145 Fujimori K, Yokoyama A, Kurita Y, Terashima M. A pilot phase 2 study of surgical treatment after induction chemotherapy for resectable stage I to IIIA small cell lung cancer.  Chest. 1997;  111 1089-1093
    PubMedGoogle Scholar
  • 146 Elias A D. Small cell lung cancer: state-of-the-art therapy in 1996.  Chest. 1996;  112 251S-258S
    PubMedGoogle Scholar
  • 147 Osterlind K, Hansen M, Hansen H H, Dombernowsky P, Rorth M. Treatment policy of surgery in small cell carcinoma of the lung: retrospective analysis of a series of 874 consecutive patients.  Thorax. 1985;  40 272-277
    CrossrefPubMedGoogle Scholar
  • 148 Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy.  Chest. 1994;  106 320S-323S
    CrossrefPubMedGoogle Scholar
  • 149 Fox W, Scadding J G. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-cell carcinoma of bronchus. Ten-year follow-up.  Lancet. 1973;  2 63-65
    PubMedGoogle Scholar
  • 150 Müler L C, Salzer G M, Huber H, Prior C, Ebner I, Frommhold H, Prauer H W. Multimodal therapy of small cell lung cancer in TNM stages I through IIIa.  Ann Thorac Surg. 1992;  54 493-497
    PubMedGoogle Scholar
  • 151 Eberhardt W, Stamatis G, Stuschke M, Wilke H, Muller M R, Kolks S, Flasshove M, Schutte J, Stahl M, Schlenger L, Budach V, Gerschuchna D, Stuben G, Teschler H, Sack H, Seeber S. Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial.  Br J Cancer. 1999;  81 1206-1212
    CrossrefPubMedGoogle Scholar
  • 152 Armstrong J. Target volume definition for three-dimensional conformal radiation therapy of lung cancer.  Br J Radiol. 1998;  71 587-594
    PubMedGoogle Scholar
  • 153 Graham M V, Prudy J A, Emamai B, Harms W, Bosch W, Lockett M A, Perez C A. Clinical dose-volume histogramm analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC).  Int J Radiat Oncol Biol Phys. 1999;  45 323-329
    PubMedGoogle Scholar
  • 154 Marks L, Munley M T, Bentel G C, Zhou S M, Hollis D, Scarfone C, Sibley G, Kong F M, Jirtle R, Jaszczak R, Coleman R E, Tapson V, Anscher M. Physical and biological predictors of changes in whole lung function following thoracic irradiation.  Int J Radiat Oncol Biol Phys. 1997;  39 563-570
    CrossrefPubMedGoogle Scholar
  • 155 Armstrong J, Raben A, Zelefsky M, Burt M, Leibel S, Burman C, Kutcher G, Harrison L, Hahn C, Ginsberg R, Rusch V, Kris M, Fuks Z. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer.  Radiother Oncol. 1997;  44 17-22
    CrossrefPubMedGoogle Scholar
  • 156 De Ruysscher D, Vansteenkiste J. Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects.  Radiother Oncol. 2000;  55 1-9
    CrossrefPubMedGoogle Scholar
  • 157 Royal College of Radiologists . Guidelines on the non-surgical management of lung cancer.  Clinical Oncology. 1999;  11 S1-S53
    CrossrefPubMedGoogle Scholar
  • 158 Cox J, Azarnia N, Byhardt R W, Shin K H, Emami B, Pajak T F. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.3 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83 - 11.  J Clin Oncol. 1990;  9 1543-1555
    PubMedGoogle Scholar
  • 159 Appold S, Baumann M, Neidt F, Herrmann T. Ergebnisse der Bestrahlung inoperabler nichtkleinzelliger Bronchialkarzinome im Stadium III mit 25 Gy in fünf Fraktionen.  Strahlenther Onkol. 1999;  175 267-270
    PubMedGoogle Scholar
  • 160 McQuay H J, Collins S L, Carroll D, Moore R A. Radiotherapy for the palliation of painful bone metastases.  Cochrane Database Syst Rev. 2000;  CD001793
    PubMedGoogle Scholar
  • 161 Coia L R, Aaronson N, Linggood R, Loeffler J, Priestman T J. A report of the consensus workshop panel on the treatment of brain metastases.  Int J Radiat Oncol Biol Phys. 1992;  23 223-227
    PubMedGoogle Scholar
  • 162 Koswig S, Budach V. Remineralisation und Schmerzlinderung von Knochenmetastasen nach unterschiedlich fraktionierter Strahlentherapie (10mal 3 Gy vs. 1 mal 8 Gy).  Strahlentherapie Onkol. 1999;  175 500-508
    CrossrefPubMedGoogle Scholar
  • 163 Nestle U, Nieder C, Walter K, Abel U, Ukena D, Sybrecht G W, Schnabel K. A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. Conventionally fractionated 60 Gy: results of a randomized equivalence study.  Int J Radiat Oncol Biol Phys. 2000;  48 95-103
    CrossrefPubMedGoogle Scholar
  • 164 Steenland E, Leer J, van Houwelingen H, Post W J, van den Hout W B, Kievit J, de Haes H, Martijn H, Oei B, Vonk E, van der Stehen-Banasik E, Wiggenraad R GJ, Hoogenhout J, Warlam-Rodenhuis C, van Tienhoven G, Wanders R, Pomp J, van Reijn M, van Mierlo T, Rutten E. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch bone metastasis study.  Radiother Oncol. 1999;  52 101-109
    CrossrefPubMedGoogle Scholar
  • 165 Wolf M, Pritsch M, Drings P, Hans K, Schroeder M, Flechtner H, Heim M, Hruska D, Mende S, Becker H, Dannhäuser J, Lohmüller R, Gropp C, Gassel W D, Holle R, Havemann K. Cyclic-alternating versus response-oriented chemotherapy in small-cell-lung cancer: a German multicenter randomized trial of 321 patients.  J Clin Oncol. 1991;  9 614-624
    PubMedGoogle Scholar
  • 166 Murray N, Livingston R B, Shepherd F A, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin J W, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clincial Trials Group and the Southwest Oncology Group.  J Clin Oncol. 1999;  8 2300-2308
    PubMedGoogle Scholar
  • 167 Souhami R L, Rudd R, Ruiz de Elvira M C, James L, Gower N, Harper P G, Tobias J S, Partridge M R, Davison A G, Trask C, Spiro S G. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.  J Clin Oncol. 1994;  12 1806-1813
    PubMedGoogle Scholar
  • 168 Arriagada R, Le Chevalier T, Pignon J P, Riviere A, Monnet I, Chomy P, Tuchais C, Tarayre M, Ruffie P. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer.  N Engl J Med. 1993;  329 1848-1852
    CrossrefPubMedGoogle Scholar
  • 169 Johnson D H, Carbone D P. Increased Dose-Intensity in Small-Cell Lung Cancer: A Failed Strategy?.  J Clini Oncol. 1999;  17 2297-2298
    PubMedGoogle Scholar
  • 170 Chute J P, Chen T, Feigal E, Simon R, Johnson D. Twenty years of Phase III Trials for Patients with Extensive-Stage Small-Cell Lung Cancer. Perceptible Progress.  J Clin Oncol. 1999;  17 1794-1801
    PubMedGoogle Scholar
  • 171 Kosmidis P A, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.  Semin Oncol. 1994;  21 23-30
    PubMedGoogle Scholar
  • 172 Medical Research Council Lung Cancer Working Party . Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer. A stopped multicentre randomised trial.  Lancet. 1996;  348 563-566
    CrossrefPubMedGoogle Scholar
  • 173 Medical Research Council Lung Cancer Working Party . Randomised trial of four-drug versus less intensive two-drug chemotherapy in the palliative treatment of patients with small cell lung cancer (SCLC) and poor prognosis.  B J Cancer. 1996;  73 406-413
    PubMedGoogle Scholar
  • 174 Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J. Topotecan an new drug in the second-line treatment of small-cell lung cancer: A phase II study of patients with refractory and sensitive disease.  J Clin Oncol. 1997;  15 2090-2096
    CrossrefPubMedGoogle Scholar
  • 175 Groen H JM, Fokkema E, Biesma B, Kwa B, van Putten J WG, Postmus P E, Smit E F. Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non-Cross-Resistant Schedule.  J Clin Oncol. 1999;  17 927-932
    PubMedGoogle Scholar
  • 176 von Pawel J, Schiller J H, Shephard F A, Fields S Z, Kleisbauer J P, Chrysson N G, Stewart D J, Clark P I, Palmer M C, Depierre A, Carmichael J, Krebs J B, Ross G, Lane S R, Gralla R. Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell lung Cancer.  J Clin Oncol. 1999;  17 658-667
    CrossrefPubMedGoogle Scholar
  • 177 Masuda N, Matusi K, Negoro S, Takifuji N, Takeda K, Yana T, Kobayashi M, Hirashima T, Kusunoki Y, Ushijima S, Kawase I, Tada T, Sawaguchi H, Fukuoka M. Combination of Irinotecan and Etoposide for treatment of refractory or relapsed small cell lung cancer.  J Clin Oncol. 1998;  16 3329-3334
    PubMedGoogle Scholar
  • 178 Ginsberg R, Vokes E, Raben A. Non-small cell lung cancer. In: DeVita V, Hellman S, Rosenberg S (Hrsg). Cancer Philadelphia: Lippincott-Raven 1997: 858
    Google Scholar
  • 179 Marino P, Preatoni A, Cantoni A, Bucceri G. Single-agent chemotherapy versus combination chemotherapy in advanced NSCLC. A quality and meta-analysis study.  Lung Cancer. 1995;  13 1-12
    CrossrefPubMedGoogle Scholar
  • 180 Lilienbaum R C, Langenberg P, Dickersin K. Single agent chemotherapy versus combination chemotherapy in patients with advanced NSCLC: A meta-analysis of response, toxicity and survival.  Cancer. 1998;  82 116-126
    CrossrefPubMedGoogle Scholar
  • 181 Perng R P, Chen Y M, Ming-Liu J, Tsai C M, Lin W C, Yang K Y, Whang-Peng J. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.  J Clin Oncol. 1997;  15 2097-2102
    PubMedGoogle Scholar
  • 182 Manegold C, Bergmann B, Chemaissani A, Dornhoff W, Drings P, Kellokumpu-Lehtinen P, Liippo K, Mattson K, von Pawel J, Ricci S, Sederholm C, Stahel R A, Wagenius G, van Walree N, ten Bokkel-Huinink W. Single agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer.  Ann Oncol. 1997;  8 525-529
    CrossrefPubMedGoogle Scholar
  • 183 Frasci G, Lorusso V, Panza N, Comella P, Nicollela G, Bianco A, De Cataldis G, Ianelli A, Bilancia D, Belli M, Massidda B, Piantedosi F, Comella G, De Iena M. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced NSCLC.  J Clin Oncol. 2000;  18 2529-2536
    PubMedGoogle Scholar
  • 184 The Elderly Lung Cancer Vinorelbine Italian Study Group (ELVIS) . Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer.  J Natl Cancer Inst. 1999;  91 66-72
    CrossrefPubMedGoogle Scholar
  • 185 Larsen H, Sörensen J B, Nielsen A L, Dombernowsky P, Hansen H. Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable NSCLC.  Ann Oncol. 1995;  6 993-997
    PubMedGoogle Scholar
  • 186 Smith I E, O'Brien M ER, Norton A, Ashley S, Webb A, Nicolson M, Hickish T, Talbot T, Mansi J. Duration of chemotherapy for advances NSCLC: A phase III randomized trial of 3 versus 6 courses of mitomycin, vinblastine, cisplatin (MVP).  Proc Am Soc Clin Oncol. 1998;  (abs. 1759)
    PubMedGoogle Scholar
  • 187 Giaccone G, Splinter T A, Debruyne C, Kho G S, Lianes P, van Zandwijk N, Penucci M C, Scagliotti G, van Meerbeeck J, van Hoesel Q, Curran D, Sahmoud T, Postmus P E. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.  J Clin Oncol. 1998;  16 2133-2141
    PubMedGoogle Scholar
  • 188 Cardenal F, Lopez-Cabrerizo P, Anton A, Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic NSCLC.  J Clin Oncol. 1999;  17 12-18
    PubMedGoogle Scholar
  • 189 Le Chevalier T, Brisgand D, Douillard J, Pujol J, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard M, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T. Randomized study of Vinorelbine and Cisplatin versus Vindesine and Cisplatin versus Vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients.  J Clin Oncol. 1994;  12 360-367
    PubMedGoogle Scholar
  • 190 Klasterski J, Sculier J, Lacoix H. et al . A randomized study comparing cisplatin or Carboplatin with etoposide in patients with advanced NSCLC. EORTC Protocol 07861.  J Clin Oncol. 1990;  8 1556-1562
    PubMedGoogle Scholar
  • 191 Biesma B, Smit E F, Postmus P E. A dose and schedule finding study of gemcitabine and etoposide in patients with progressive NSCLC after platinum containing chemotherapy.  Lung Cancer. 1999;  24 115-121
    CrossrefPubMedGoogle Scholar
  • 192 Fossella F, DeVore R, Kerr R, Crawford J, Natale R, Dunphy F, Kalman L, Miller V, Lee J, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza S, Hammershaimb L. and the TAX 320 non-small cell lung cancer study group . Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens.  J Clin Oncol. 2000;  18 2354-2362
    CrossrefPubMedGoogle Scholar
  • 193 Shepherd F A, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of Docetaxel versus best Supportive Care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.  J Clin Oncol. 2000;  18 2095-2103
    CrossrefPubMedGoogle Scholar
  • 194 Sutedja G, Postmus P E. Bronchoscopic treatment of lung tumors.  Lung cancer. 1994;  11 1-117
    PubMedGoogle Scholar
  • 195 Venmans B J, van Boxem T J, Smit E F, Postmus P E, Sutedja T G. Outcome of bronchial carcinoma in situ.  Chest. 2000;  117 1572-1576
    CrossrefPubMedGoogle Scholar
  • 196 Sheski F D, Mathur P N. Endoscopic treatment of early-stage lung cancer.  Cancer Control. 2000;  7 35-44
    PubMedGoogle Scholar
  • 197 Koike T, Terashima M, Takizawa T, Tsukada H, Yokoyama A, Kurita Y, Honma K. Surgical results for centrally-located early stage lung cancer.  Ann Thorac Surg. 2000;  70 1176-1179
    CrossrefPubMedGoogle Scholar
  • 198 Johnson B E. Second lung cancer in patients after treatment for an initial lung cancer.  J Natl Cancer Inst. 1998;  90 1335-1345
    CrossrefPubMedGoogle Scholar
  • 199 Edell E S, Cotese D A. Photodynamic therapy in the management of early superficial squamous cell carcinoma as an alternative to surgical resection.  Chest. 1992;  102 1319-1322
    CrossrefPubMedGoogle Scholar
  • 200 Perol M, Caliandro R, Pommier P, Malet C, Montbarbon X, Carrie C, Ardiet J M. Curative irradiation of limited carcinomas with high-dose brachytherapy.  Chest. 1997;  111 1417-1423
    PubMedGoogle Scholar
  • 201 van Boxem T J, Venmans B J, Schramel F M, van Mourik J C, Golding R P, Postmus P E, Sutedja T G. Radiographically occult lung cancer treated with fibreoptic bronchoscopic electrocautery: a pilot study of a simple and inexpensive technique.  Eur Respir J. 1998;  11 169-172
    CrossrefPubMedGoogle Scholar
  • 202 Deygas N, Froudarakis M E, Ozenne G, Jouve S, Fournel P, Vergnon J M. Cryotherapy in early superficial bronchogenic carcinoma.  Eur Respir J. 1998;  12 (Suppl 28) 266
    PubMedGoogle Scholar
  • 203 Furuse K, Fukuoka M, Kato H, Horrai T, Kubota T, Kodama N, Kusunoki Y, Takifuji N, Okunaka T, Konaka C, Wada H, Hayata Y. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer.  J Clin Oncol. 1993;  11 1852-1857
    PubMedGoogle Scholar
  • 204 Kato H, Okunaka T, Shimatani H. Photodynamic therapy for early stage bronchogenic carcinoma.  J Clin Laser Med Surg. 1996;  14 235-238
    PubMedGoogle Scholar
  • 205 Cortese D A, Edell E S, Kinsey J H. Photodynamic therapy for early stage squamous cell carcinoma of the lung.  Mayo Clin Proc. 1997;  72 595-602
    PubMedGoogle Scholar
  • 206 Martini N. Surgical treatment of non-small cell lung cancer by stage.  Semin Surg Oncol. 1990;  6 248-254
    PubMedGoogle Scholar
  • 207 Kotlyarov E, Rukosuyev A A. Long-term results and patterns of disease recurrence after radical operations for lung cancer.  J Thorac Cardiovasc Surg. 1991;  102 24-28
    PubMedGoogle Scholar
  • 208 The Lung Cancer Study Group . Patterns of failure in patients with resected stage I und II non-small cell carcinoma of the lung.  Ann Surg. 1987;  205 67
    PubMedGoogle Scholar
  • 209 Pairolero P C, Williams D E, Bergstralh E J, Piehler J M, Bernatz P E, Payne W S. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease.  Ann Thorac Surg. 1984;  38 331-338
    CrossrefPubMedGoogle Scholar

Priv.-Doz. Dr. med. M. Thomas

Klinik für Hämatologie, Onkologie und Pneumologie Medizinische Klinik A, Universitätsklinikum Münster

Albert-Schweizer Str. 33

48149 Münster

Email: mthomas@uni-muenster.de

      >